Scholtz & Company LLC Raises Stock Position in DexCom, Inc. $DXCM

Scholtz & Company LLC grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 77,334 shares of the medical device company’s stock after acquiring an additional 8,686 shares during the period. DexCom comprises about 2.6% of Scholtz & Company LLC’s holdings, making the stock its 13th biggest position. Scholtz & Company LLC’s holdings in DexCom were worth $5,208,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Plato Investment Management Ltd acquired a new position in DexCom during the second quarter worth about $782,000. Aurora Investment Counsel purchased a new stake in shares of DexCom in the second quarter valued at $2,340,000. E Fund Management Co. Ltd. acquired a new stake in shares of DexCom during the second quarter valued at $1,273,000. SWS Partners purchased a new stake in DexCom during the 2nd quarter worth about $2,896,000. Finally, Performance Wealth Partners LLC acquired a new position in DexCom in the 2nd quarter valued at about $1,740,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DexCom stock opened at $83.88 on Thursday. The business’s fifty day moving average price is $82.25 and its 200 day moving average price is $72.65. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $31.65 billion, a P/E ratio of 33.15, a PEG ratio of 1.42 and a beta of 1.42.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm’s revenue was up 13.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.48 earnings per share. As a group, research analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current year.

Insider Buying and Selling at DexCom

In related news, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the transaction, the insider owned 328,970 shares in the company, valued at approximately $25,106,990.40. This trade represents a 7.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,777 shares of company stock worth $4,950,714 in the last quarter. Company insiders own 0.28% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Wells Fargo & Company lifted their price target on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft began coverage on shares of DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 target price for the company. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the company a “buy” rating in a report on Monday, August 3rd. Truist Financial set a $93.00 price objective on shares of DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Robert W. Baird set a $105.00 price objective on shares of DexCom in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.